Introduction Intralesional injection of oncolytic viral immunotherapies leads to apoptosis of tumour cells and induction of an immune response. Talimogene laherparepvec (T-VEC) is approved for the treatment of malignant melanoma in non-resectable and metastatic settings.
No takes yet. Share an insight, caveat, or question.
Stähr et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: